Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 46

1.

Hyperfiltration predicts long-term renal outcomes in humanized sickle cell mice.

Kasztan M, Fox BM, Lebensburger JD, Hyndman KA, Speed JS, Pollock JS, Pollock DM.

Blood Adv. 2019 May 14;3(9):1460-1475. doi: 10.1182/bloodadvances.2018028878.

2.

Effect of Sickle Cell Anemia Therapies on the Natural History of Growth and Puberty Patterns.

Nagalapuram V, Kulkarni V, Leach J, Aban I, Sirigaddi K, Lebensburger JD, Iyer P.

J Pediatr Hematol Oncol. 2019 Apr 3. doi: 10.1097/MPH.0000000000001477. [Epub ahead of print]

PMID:
30951025
3.

Roseamonas gilardii Bacteremia in a Patient With HbSβ0-thalassemia: Clinical Implications and Literature Review.

Schlappi C, Bernstock JD, Ricketts W, Nix GA, Poole C, Lebensburger J, Friedman GK.

J Pediatr Hematol Oncol. 2019 Apr 3. doi: 10.1097/MPH.0000000000001476. [Epub ahead of print]

PMID:
30951022
4.

Children with sickle cell anemia and APOL1 genetic variants develop albuminuria early in life.

Zahr RS, Rampersaud E, Kang G, Weiss MJ, Wu G, Davis RL, Hankins JS, Estepp JH, Lebensburger J.

Haematologica. 2019 Sep;104(9):e385-e387. doi: 10.3324/haematol.2018.212779. Epub 2019 Mar 19. No abstract available.

5.

Hyperfiltration during early childhood precedes albuminuria in pediatric sickle cell nephropathy.

Lebensburger JD, Aban I, Pernell B, Kasztan M, Feig DI, Hilliard LM, Askenazi DJ.

Am J Hematol. 2019 Apr;94(4):417-423. doi: 10.1002/ajh.25390. Epub 2019 Jan 8.

PMID:
30592084
6.

Hydroxyurea prevents onset and progression of albuminuria in children with sickle cell anemia.

Zahr RS, Hankins JS, Kang G, Li C, Wang WC, Lebensburger J, Estepp JH.

Am J Hematol. 2019 Jan;94(1):E27-E29. doi: 10.1002/ajh.25329. Epub 2018 Nov 29. No abstract available.

PMID:
30359463
7.

Hypomorphic caspase activation and recruitment domain 11 (CARD11) mutations associated with diverse immunologic phenotypes with or without atopic disease.

Dorjbal B, Stinson JR, Ma CA, Weinreich MA, Miraghazadeh B, Hartberger JM, Frey-Jakobs S, Weidinger S, Moebus L, Franke A, Schäffer AA, Bulashevska A, Fuchs S, Ehl S, Limaye S, Arkwright PD, Briggs TA, Langley C, Bethune C, Whyte AF, Alachkar H, Nejentsev S, DiMaggio T, Nelson CG, Stone KD, Nason M, Brittain EH, Oler AJ, Veltri DP, Leahy TR, Conlon N, Poli MC, Borzutzky A, Cohen JI, Davis J, Lambert MP, Romberg N, Sullivan KE, Paris K, Freeman AF, Lucas L, Chandrakasan S, Savic S, Hambleton S, Patel SY, Jordan MB, Theos A, Lebensburger J, Atkinson TP, Torgerson TR, Chinn IK, Milner JD, Grimbacher B, Cook MC, Snow AL.

J Allergy Clin Immunol. 2019 Apr;143(4):1482-1495. doi: 10.1016/j.jaci.2018.08.013. Epub 2018 Aug 28.

8.

Red blood cell transfusion therapy for sickle cell patients with frequent painful events.

Hilliard LM, Kulkarni V, Sen B, Caldwell C, Bemrich-Stolz C, Howard TH, Brandow A, Waite E, Lebensburger JD.

Pediatr Blood Cancer. 2018 Dec;65(12):e27423. doi: 10.1002/pbc.27423. Epub 2018 Aug 27.

PMID:
30152184
9.

Impact of early analgesia on hospitalization outcomes for sickle cell pain crisis.

Payne J, Aban I, Hilliard LM, Madison J, Bemrich-Stolz C, Howard TH, Brandow A, Waite E, Lebensburger JD.

Pediatr Blood Cancer. 2018 Dec;65(12):e27420. doi: 10.1002/pbc.27420. Epub 2018 Aug 27.

PMID:
30151977
10.

Outcomes of febrile events in pediatric patients with sickle cell anemia.

Sirigaddi K, Aban I, Jantz A, Pernell BM, Hilliard LM, Bhatia S, Lebensburger JD.

Pediatr Blood Cancer. 2018 Nov;65(11):e27379. doi: 10.1002/pbc.27379. Epub 2018 Aug 1.

PMID:
30070043
11.

Outcomes in Mild to Moderate Isolated Thrombocytopenia.

Schlappi C, Kulkarni V, Palabindela P, Bemrich-Stolz C, Howard T, Hilliard L, Lebensburger J.

Pediatrics. 2018 Jul;142(1). pii: e20173804. doi: 10.1542/peds.2017-3804. Epub 2018 Jun 11.

12.

Sickle Cell Clinical Research and Intervention Program (SCCRIP): A lifespan cohort study for sickle cell disease progression from the pediatric stage into adulthood.

Hankins JS, Estepp JH, Hodges JR, Villavicencio MA, Robison LL, Weiss MJ, Kang G, Schreiber JE, Porter JS, Kaste SC, Saving KL, Bryant PC, Deyo JE, Nottage KA, King AA, Brandow AM, Lebensburger JD, Adesina O, Chou ST, Zemel BS, Smeltzer MP, Wang WC, Gurney JG.

Pediatr Blood Cancer. 2018 Sep;65(9):e27228. doi: 10.1002/pbc.27228. Epub 2018 May 24.

PMID:
29797644
13.

Acute Kidney Injury during Parvovirus B19-Induced Transient Aplastic Crisis in Sickle Cell Disease.

Oakley J, Zahr R, Aban I, Kulkarni V, Patel RP, Hurwitz J, Askenazi D, Hankins J, Lebensburger J.

Am J Hematol. 2018 May 14. doi: 10.1002/ajh.25140. [Epub ahead of print] No abstract available.

14.

Management of severe chronic pain with methadone in pediatric patients with sickle cell disease.

LeBlanc Z, Vance C, Payne J, Zhang J, Hilliard L, Lebensburger JD, Howard TH.

Pediatr Blood Cancer. 2018 Aug;65(8):e27084. doi: 10.1002/pbc.27084. Epub 2018 May 11.

PMID:
29749702
15.

Evaluating risk factors for chronic kidney disease in pediatric patients with sickle cell anemia.

Lebensburger JD, Cutter GR, Howard TH, Muntner P, Feig DI.

Pediatr Nephrol. 2017 Sep;32(9):1565-1573. doi: 10.1007/s00467-017-3658-8. Epub 2017 Apr 5.

16.

Acute kidney injury during a pediatric sickle cell vaso-occlusive pain crisis.

Baddam S, Aban I, Hilliard L, Howard T, Askenazi D, Lebensburger JD.

Pediatr Nephrol. 2017 Aug;32(8):1451-1456. doi: 10.1007/s00467-017-3623-6. Epub 2017 Feb 25.

17.

Publication outcomes of abstracts from the American Society of Hematology Annual Meeting.

Baddam S, Cutter GR, Wolfson JA, Friedman GK, Lebensburger JD.

Am J Hematol. 2017 May;92(5):E81-E83. doi: 10.1002/ajh.24695. Epub 2017 Mar 20. No abstract available.

18.

Hydroxycarbamide for patients with silent cerebral infarcts: outcomes and patient preference.

Rushton T, Aban I, Young D, Howard T, Hilliard L, Lebensburger J.

Br J Haematol. 2018 Apr;181(1):145-148. doi: 10.1111/bjh.14526. Epub 2017 Jan 20. Review. No abstract available.

PMID:
28107562
19.

Severe anemia early in life as a risk factor for sickle-cell kidney disease.

Aban I, Baddam S, Hilliard LM, Howard TH, Feig DI, Lebensburger JD.

Blood. 2017 Jan 19;129(3):385-387. doi: 10.1182/blood-2016-09-738104. Epub 2016 Dec 5. No abstract available.

20.

Maintaining High Level of Care at Satellite Sickle Cell Clinics.

Hamm J, Hilliard L, Howard T, Lebensburger J.

J Health Care Poor Underserved. 2016;27(1):280-292.

21.

Absorbance and redox based approaches for measuring free heme and free hemoglobin in biological matrices.

Oh JY, Hamm J, Xu X, Genschmer K, Zhong M, Lebensburger J, Marques MB, Kerby JD, Pittet JF, Gaggar A, Patel RP.

Redox Biol. 2016 Oct;9:167-177. doi: 10.1016/j.redox.2016.08.003. Epub 2016 Aug 10.

22.

Elective cholecystectomy reduces morbidity of cholelithiasis in pediatric sickle cell disease.

Goodwin EF, Partain PI, Lebensburger JD, Fineberg NS, Howard TH.

Pediatr Blood Cancer. 2017 Jan;64(1):113-120. doi: 10.1002/pbc.26179. Epub 2016 Sep 19.

PMID:
27643455
23.

Cranial epidural hematomas: A case series and literature review of this rare complication associated with sickle cell disease.

Hamm J, Rathore N, Lee P, LeBlanc Z, Lebensburger J, Meier ER, Kwiatkowski JL.

Pediatr Blood Cancer. 2017 Mar;64(3). doi: 10.1002/pbc.26237. Epub 2016 Sep 13. Review.

PMID:
27618802
24.

Prevalence of acute kidney injury during pediatric admissions for acute chest syndrome.

Lebensburger JD, Palabindela P, Howard TH, Feig DI, Aban I, Askenazi DJ.

Pediatr Nephrol. 2016 Aug;31(8):1363-8. doi: 10.1007/s00467-016-3370-0. Epub 2016 Mar 24.

25.

Exploring Adult Care Experiences and Barriers to Transition in Adult Patients with Sickle Cell Disease.

Bemrich-Stolz CJ, Halanych JH, Howard TH, Hilliard LM, Lebensburger JD.

Int J Hematol Ther. 2015;1(1). doi: 10.15436/2381-1404.15.003. Epub 2015 Sep 6.

26.

Hydroxyurea decreases hospitalizations in pediatric patients with Hb SC and Hb SB+ thalassemia.

Lebensburger JD, Patel RJ, Palabindela P, Bemrich-Stolz CJ, Howard TH, Hilliard LM.

J Blood Med. 2015 Dec 15;6:285-90. doi: 10.2147/JBM.S97405. eCollection 2015.

27.

Systematic review of interventional sickle cell trials registered in ClinicalTrials.gov.

Lebensburger JD, Hilliard LM, Pair LE, Oster R, Howard TH, Cutter GR.

Clin Trials. 2015 Dec;12(6):575-83. doi: 10.1177/1740774515590811. Epub 2015 Jun 17. Review.

28.

Encephaloduroarteriosynangiosis and encephalomyoarteriosynangiosis for treatment of moyamoya syndrome in pediatric patients with sickle cell disease.

Griessenauer CJ, Lebensburger JD, Chua MH, Fisher WS 3rd, Hilliard L, Bemrich-Stolz CJ, Howard TH, Johnston JM.

J Neurosurg Pediatr. 2015 Jul;16(1):64-73. doi: 10.3171/2014.12.PEDS14522. Epub 2015 Apr 3.

PMID:
25837886
29.

13-valent pneumococcal conjugate vaccine (PCV13) is immunogenic and safe in children 6-17 years of age with sickle cell disease previously vaccinated with 23-valent pneumococcal polysaccharide vaccine (PPSV23): Results of a phase 3 study.

De Montalembert M, Abboud MR, Fiquet A, Inati A, Lebensburger JD, Kaddah N, Mokhtar G, Piga A, Halasa N, Inusa B, Rees DC, Heath PT, Telfer P, Driscoll C, Al Hajjar S, Tozzi A, Jiang Q, Emini EA, Gruber WC, Gurtman A, Scott DA.

Pediatr Blood Cancer. 2015 Aug;62(8):1427-36. doi: 10.1002/pbc.25502. Epub 2015 Mar 23. Erratum in: Pediatr Blood Cancer. 2019 Feb;66(2):e27554.

PMID:
25810327
30.

Understanding and improving health education among first-time parents of infants with sickle cell anemia in Alabama: a mixed methods approach.

Lebensburger JD, Grosse SD, Altice JL, Thierry JM, Ivankova NV.

J Pediatr Hematol Oncol. 2015 Jan;37(1):35-42. doi: 10.1097/MPH.0000000000000217.

31.

Patient-centered approach to designing sickle cell transition education.

Williams CP, Smith CH, Osborn K, Bemrich-Stolz CJ, Hilliard LM, Howard TH, Lebensburger JD.

J Pediatr Hematol Oncol. 2015 Jan;37(1):43-7. doi: 10.1097/MPH.0000000000000169.

PMID:
24807007
32.

Ferritin and LIC: predicting liver injury in children with sickle cell.

Smith E, Lebensburger J, Hilliard L, Kelly D, Fineberg N, Bai S, Howard T.

J Pediatr Gastroenterol Nutr. 2014 Mar;58(3):387-90. doi: 10.1097/MPG.0000000000000235.

PMID:
24553473
33.

Social skills and executive function among youth with sickle cell disease: a preliminary investigation.

Hensler M, Wolfe K, Lebensburger J, Nieman J, Barnes M, Nolan W, King A, Madan-Swain A.

J Pediatr Psychol. 2014 Jun;39(5):493-500. doi: 10.1093/jpepsy/jst138. Epub 2014 Jan 14.

34.

Exploring barriers and facilitators to clinical trial enrollment in the context of sickle cell anemia and hydroxyurea.

Lebensburger JD, Sidonio RF, Debaun MR, Safford MM, Howard TH, Scarinci IC.

Pediatr Blood Cancer. 2013 Aug;60(8):1333-7. doi: 10.1002/pbc.24486. Epub 2013 Feb 15.

35.

Barriers in transition from pediatrics to adult medicine in sickle cell anemia.

Lebensburger JD, Bemrich-Stolz CJ, Howard TH.

J Blood Med. 2012;3:105-12. doi: 10.2147/JBM.S32588. Epub 2012 Sep 19.

36.

Hydroxyurea treatment of children with hemoglobin SC disease.

Yates AM, Dedeken L, Smeltzer MP, Lebensburger JD, Wang WC, Robitaille N.

Pediatr Blood Cancer. 2013 Feb;60(2):323-5. doi: 10.1002/pbc.24283. Epub 2012 Sep 4.

PMID:
22949140
37.

Impact of hydroxyurea on clinical events in the BABY HUG trial.

Thornburg CD, Files BA, Luo Z, Miller ST, Kalpatthi R, Iyer R, Seaman P, Lebensburger J, Alvarez O, Thompson B, Ware RE, Wang WC; BABY HUG Investigators.

Blood. 2012 Nov 22;120(22):4304-10; quiz 4448. doi: 10.1182/blood-2012-03-419879. Epub 2012 Aug 22. Erratum in: Blood. 2016 Dec 15;128(24):2869.

38.

Influence of severity of anemia on clinical findings in infants with sickle cell anemia: analyses from the BABY HUG study.

Lebensburger JD, Miller ST, Howard TH, Casella JF, Brown RC, Lu M, Iyer RV, Sarnaik S, Rogers ZR, Wang WC; BABY HUG Investigators.

Pediatr Blood Cancer. 2012 Oct;59(4):675-8. doi: 10.1002/pbc.24037. Epub 2011 Dec 20.

39.

What is the evidence for using hydroxyurea for secondary stroke prevention?

Lebensburger JD, DeBaun MR, Thompson AA.

Hematology Am Soc Hematol Educ Program. 2011;2011:440-2. doi: 10.1182/asheducation-2011.1.440. Review.

PMID:
22160071
40.

Hydroxyurea therapy of a murine model of sickle cell anemia inhibits the progression of pneumococcal disease by down-modulating E-selectin.

Lebensburger JD, Howard T, Hu Y, Pestina TI, Gao G, Johnson M, Zakharenko SS, Ware RE, Tuomanen EI, Persons DA, Rosch JW.

Blood. 2012 Feb 23;119(8):1915-21. doi: 10.1182/blood-2011-08-374447. Epub 2011 Nov 30.

41.

Laboratory and clinical correlates for magnetic resonance imaging (MRI) abnormalities in pediatric sickle cell anemia.

Lebensburger JD, Hilliard LM, McGrath TM, Fineberg NS, Howard TH.

J Child Neurol. 2011 Oct;26(10):1260-4. doi: 10.1177/0883073811405054. Epub 2011 May 13.

PMID:
21572054
42.

Protective role of hemoglobin and fetal hemoglobin in early kidney disease for children with sickle cell anemia.

Lebensburger J, Johnson SM, Askenazi DJ, Rozario NL, Howard TH, Hilliard LM.

Am J Hematol. 2011 May;86(5):430-2. doi: 10.1002/ajh.21994.

43.

Hydroxyurea therapy requires HbF induction for clinical benefit in a sickle cell mouse model.

Lebensburger JD, Pestina TI, Ware RE, Boyd KL, Persons DA.

Haematologica. 2010 Sep;95(9):1599-603. doi: 10.3324/haematol.2010.023325. Epub 2010 Apr 7.

44.

Bronchioloalveolar carcinoma as a second malignancy in osteosarcoma survivors.

Lebensburger J, Katzenstein H, Jenkins JJ, Rodriguez-Galindo C.

Pediatr Blood Cancer. 2009 Sep;53(3):499-501. doi: 10.1002/pbc.22005.

PMID:
19418544
45.

Biloma and pneumobilia in sickle cell disease.

Lebensburger J, Esbenshade A, Blakely M, Hankins J, Wang W.

Pediatr Blood Cancer. 2008 Aug;51(2):288-90. doi: 10.1002/pbc.21575.

PMID:
18421713
46.

Progress toward safe and effective gene therapy for beta-thalassemia and sickle cell disease.

Lebensburger J, Persons DA.

Curr Opin Drug Discov Devel. 2008 Mar;11(2):225-32. Review.

PMID:
18283610

Supplemental Content

Loading ...
Support Center